Uwell Biopharma Income Statement

Financials in millions TWD. Fiscal year is January - December.

Millions TWD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2019	FY 2018
Period Ending	Jun '25 Jun 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018
Revenue	0.45	0.45	-	-	-	-
Cost of Revenue	0.15	0.15	-	-	-	-
Gross Profit	0.3	0.3	-	-	-	-
Selling, General & Admin	11.07	11.09	11.47	11.52	0.76	1.01
Research & Development	44.67	32.63	37.18	38.51	19.83	15.87
Operating Expenses	55.74	43.72	48.64	50.03	20.59	16.87
Operating Income	-55.44	-43.42	-48.64	-50.03	-20.59	-16.87
Interest Expense	-0.17	-0.21	-0.22	-0.28	-0.07	-
Interest & Investment Income	0.75	0.83	0.62	0.26	0.17	0.01
Currency Exchange Gain (Loss)	-	-	-	-	0	0.01
Other Non Operating Income (Expenses)	0	1.92	3.08	8.58	0.01	0.02
Pretax Income	-54.86	-40.87	-45.17	-41.47	-20.48	-16.84
Net Income	-54.86	-40.87	-45.17	-41.47	-20.48	-16.84
Net Income to Common	-54.86	-40.87	-45.17	-41.47	-20.48	-16.84
Shares Outstanding (Basic)	117	117	89	57	17	6
Shares Outstanding (Diluted)	117	117	89	57	17	6
Shares Change (YoY)	105.26%	31.62%	55.95%	245.45%	155.89%	-
EPS (Basic)	-0.47	-0.35	-0.51	-0.73	-1.24	-2.61
EPS (Diluted)	-0.47	-0.35	-0.51	-0.73	-1.24	-2.61
Free Cash Flow	-40.38	-32.38	-42.64	-35.86	-19.27	-17.67
Free Cash Flow Per Share	-0.34	-0.28	-0.48	-0.63	-1.17	-2.74
Gross Margin	66.89%	66.89%	-	-	-	-
Operating Margin	-12320.44%	-9648.00%	-	-	-	-
Profit Margin	-12190.89%	-9082.67%	-	-	-	-
Free Cash Flow Margin	-8972.67%	-7196.22%	-	-	-	-
EBITDA	-52.36	-40.32	-45.53	-47.15	-20.5	-16.85
D&A For EBITDA	3.09	3.1	3.12	2.88	0.09	0.03
EBIT	-55.44	-43.42	-48.64	-50.03	-20.59	-16.87

Source: S&P Global Market Intelligence. Standard template. Financial Sources.